News from catabasis pharmaceuticals, inc

Mar 14, 2014, 08:00 ET

Catabasis to Present Data on CAT-1004 at the Muscular Dystrophy Association's 2014 Clinical Conference

 Catabasis Pharmaceuticals Inc. today announced that data from its Phase 1 clinical trial of SMART Linker conjugate CAT-1004 will be presented...

Feb 26, 2014, 08:00 ET

Catabasis Names Andrew Nichols, Ph.D., Vice President of Research

 Catabasis Pharmaceuticals Inc. today announced that it has named Andrew Nichols, Ph.D., to the newly-created position of vice president of...

Feb 04, 2014, 08:00 ET

Catabasis Announces Appointment of Kenneth M. Bate as Independent Director

Catabasis Pharmaceuticals Inc. today announced the appointment of Kenneth M. Bate to its board of directors as an independent director. Mr. Bate is...

Jan 08, 2014, 08:00 ET

Catabasis to Present at 32nd Annual J.P. Morgan Healthcare Conference

 Catabasis Pharmaceuticals Inc. today announced that Jill Milne, Ph.D., Catabasis' co-founder and chief executive officer, will present an...

Dec 05, 2013, 08:00 ET

Catabasis Initiates Phase 2 Trial of CAT-2003 in Patients with Severe Hypertriglyceridemia

 Catabasis Pharmaceuticals, Inc., today announced the initiation of a Phase 2 clinical trial investigating the safety and efficacy of CAT-2003...

Nov 15, 2013, 00:01 ET

Catabasis Closes $32.4 Million Series B Financing

 Catabasis Pharmaceuticals, Inc., today announced it has completed a $32.4 million Series B financing round led by new investor Lightstone...

Nov 13, 2013, 08:00 ET

Catabasis Names Ian Sanderson Chief Financial Officer

Catabasis Pharmaceuticals, Inc., today announced that it has named Ian Sanderson its chief financial officer. Mr. Sanderson brings to Catabasis...

Aug 28, 2013, 08:00 ET

Catabasis to Present Phase 1 Data from Oral SMART Linker Conjugate CAT-2003 at Upcoming Conference

Catabasis Pharmaceuticals, Inc., today announced that new clinical data on the inhibition of PCSK9* by its oral SMART Linker conjugate, CAT-2003,...

Aug 21, 2013, 08:00 ET

Catabasis Initiates Phase 2 Trial of CAT-2003 in Patients with Hypertriglyceridemia and Hypercholesterolemia

 Catabasis Pharmaceuticals Inc. today announced the initiation of PATHWAYS I*, a Phase 2 trial investigating the safety, tolerability and...

Jul 30, 2013, 08:00 ET

Catabasis' CAT-2003 Demonstrates Significant Reduction of Fasting and Post-Prandial Triglycerides in Successful Phase 1 Trial

 Catabasis Pharmaceuticals, Inc., today announced that preliminary data from a Phase 1 trial of CAT-2003, an oral SMART Linker conjugate...

Apr 30, 2013, 12:15 ET

Catabasis Pharmaceuticals Announces Issuance of Patents for CAT-1000 and CAT-2000 Series

 Catabasis Pharmaceuticals Inc., announced that the United States Patent and Trademark Office has issued patents that cover CAT-1000 and...

Mar 26, 2013, 08:00 ET

Catabasis Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia

 Catabasis Pharmaceuticals Inc., today announced the initiation of a Phase 1 study to investigate the safety and tolerability of...

Feb 11, 2013, 08:00 ET

Catabasis Announces Positive Phase 1 Data for CAT-1004 Validating the SMART Linker Technology Platform

 Catabasis Pharmaceuticals, Inc., today announced that a three-part series of Phase 1 studies showed that CAT-1004, a SMART Linker conjugate of...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
ReportBuyer
Investor-Edge